IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 115 filers reported holding IMMUNOVANT INC in Q1 2022. The put-call ratio across all filers is 0.11 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $4,487,221 | -25.3% | 236,543 | -38.9% | 0.02% | -30.0% |
| Q1 2023 | $6,007,287 | +64.4% | 387,317 | +88.2% | 0.03% | +50.0% |
| Q4 2022 | $3,653,554 | +137.7% | 205,834 | +14.1% | 0.02% | +150.0% |
| Q4 2021 | $1,537,000 | -51.7% | 180,395 | -50.7% | 0.01% | -60.0% |
| Q3 2021 | $3,179,000 | -18.4% | 365,793 | -0.8% | 0.02% | -25.9% |
| Q2 2021 | $3,897,000 | -43.5% | 368,729 | -14.3% | 0.03% | -46.0% |
| Q1 2021 | $6,897,000 | – | 430,015 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alpine Global Management, LLC | 4,448,017 | $17,347,000 | 4.39% |
| Deep Track Capital, LP | 9,455,000 | $36,875,000 | 2.42% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 233 | $60,000,000 | 0.63% |
| Octagon Capital Advisors LP | 579,061 | $2,258,000 | 0.60% |
| Eventide Asset Management | 5,372,512 | $20,953,000 | 0.45% |
| WITTENBERG INVESTMENT MANAGEMENT, INC. | 174,000 | $679,000 | 0.29% |
| Frazier Life Sciences Management, L.P. | 585,759 | $2,284,000 | 0.22% |
| BCK CAPITAL MANAGEMENT LP | 54,293 | $212,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 777,590 | $3,033,000 | 0.12% |
| Bridgefront Capital, LLC | 15,649 | $61,000 | 0.07% |